We demonstrated that KAT/3BP exhibits both in vitro and in vivo cytotoxic activity in lymphoma models as a single agent, with efficacy maintained in models harboring secondary resistance to BTK, BCL2, and PI3K inhibitors. The gene discussed is BCL2; the disease is lymphoma.